Kiniksa Pharmaceuticals

Benin
Klouékanmè, Kouffo, Benin, HM 11

Company profile

Kiniksa Pharmaceuticals company profile

Kiniksa Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with a significant unmet medical need. It has a pipeline of product candidates across various stages of development, currently focused on autoinflammatory and autoimmune conditions. It has three clinical-stage product candidates, one of which is anticipated to commence a Phase 3 clinical trial in 2018. They follow a disciplined and methodical approach to selectively identify and acquire product candidates with strong biologic rationales or validated mechanisms of action. The company's portfolio of product candidates offers multiple development opportunities. By modulating different parts of the innate and adaptive immune system, these product candidates together have the potential to provide a variety of mechanisms to address multiple devastating diseases.

Business identity

Contact email
[email protected]
Phone number
(781) 431-9100
Operating status
Active
Company type
For Profit
Employee range
251-500 employees
Revenue range
$10M-$100M
Founded
2015-01-01, Year

Headquarters

Postal code
HM 11
Country code
BJ
Continent
Africa

Capital profile

Funding and company signals

Funding stage
IPO
Funding rounds
4
Total equity funding
$400M
Last funding
Post IPO Equity / $80M / 2020-05-13
Last equity funding
Post IPO Equity / $80M
Investors
7
Lead investors
1
Articles
121
Exited on
2018-05-23

Founders and investors

Lead investors

Baker Brothers Advisors LLC

Investors

Cormorant Asset ManagementDeerfieldFidelitySofinnova InvestmentsVenrock Healthcare Capital Partners